6BR2

Structure of RORgt in complex with a novel isoquinoline inverse agonist.

6BR2 の概要

• エントリーDOI: 10.2210/pdb6br2/pdb
• 分子名称: Nuclear receptor ROR-gamma, (4S)-2-METHYL-2,4-PENTANEDIOL, (1R)-N-(4-tert-butyl-3-fluorophenyl)-6-methoxy-2-[(3-oxo-2,3-dihydro-1,2-oxazol-5-yl)acetyl]-1,2,3,4-tetrahydroisoquinoline-1-carboxamide, ... (4 entities in total)
• 機能のキーワード: nuclear hormone receptor, inverse agonist, complex, transcription-agonist complex, transcription/agonist
• 由来する生物種: Homo sapiens (Human)
• 細胞内の位置: Nucleus : P51449
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 51201.21

構造登録者

Skene, R.J.,Hoffman, I. (登録日: 2017-11-29, 公開日: 2018-03-21, 最終更新日: 2024-03-13)

主引用文献

Kono, M.,Ochida, A.,Oda, T.,Imada, T.,Banno, Y.,Taya, N.,Masada, S.,Kawamoto, T.,Yonemori, K.,Nara, Y.,Fukase, Y.,Yukawa, T.,Tokuhara, H.,Skene, R.,Sang, B.C.,Hoffman, I.D.,Snell, G.P.,Uga, K.,Shibata, A.,Igaki, K.,Nakamura, Y.,Nakagawa, H.,Tsuchimori, N.,Yamasaki, M.,Shirai, J.,Yamamoto, S.
Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor gamma t Inverse Agonist.
J. Med. Chem., 61:2973-2988, 2018

PubMed Abstract: A series of tetrahydronaphthyridine derivatives as novel RORγt inverse agonists were designed and synthesized. We reduced the lipophilicity of tetrahydroisoquinoline compound 1 by replacement of the trimethylsilyl group and SBDD-guided scaffold exchange, which successfully afforded compound 7 with a lower log  D value and tolerable in vitro activity. Consideration of LLE values in the subsequent optimization of the carboxylate tether led to the discovery of [ cis-3-({(5 R)-5-[(7-fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic acid, TAK-828F (10), which showed potent RORγt inverse agonistic activity, excellent selectivity against other ROR isoforms and nuclear receptors, and a good pharmacokinetic profile. In animal studies, oral administration of compound 10 exhibited robust and dose-dependent inhibition of IL-17A cytokine expression in a mouse IL23-induced gene expression assay. Furthermore, development of clinical symptoms in a mouse experimental autoimmune encephalomyelitis model was significantly reduced. Compound 10 was selected as a clinical compound for the treatment of Th17-driven autoimmune diseases.

PubMed: 29510038
DOI: 10.1021/acs.jmedchem.8b00061

実験手法

X-RAY DIFFRACTION (3.18 Å)